|
11 Sep 2025 |
Emami
|
Consensus Share Price Target
|
602.05 |
710.46 |
- |
18.01 |
buy
|
|
|
|
|
26 Aug 2025
|
Emami
|
Khambatta Securities
|
602.05
|
698.00
|
585.45
(2.84%)
|
15.94 |
Buy
|
|
|
Emami's performance in 1Q FY26 was impacted by external factors like unseasonal weather which particularly affected its summer-focused portfolio. Despite these challenges, the company's core domestic business, excluding talc, demonstrated resilience with a 6% y-o-y revenue growth.
|
|
07 Aug 2025
|
Emami
|
Sharekhan
|
602.05
|
690.00
|
582.20
(3.41%)
|
14.61 |
Buy
|
|
|
Emami’s Q1FY26 performance beat estimates on all fronts, despite a weak summer which hit revenue growth of summer-centric portfolio.
|
|
31 Jul 2025
|
Emami
|
Motilal Oswal
|
602.05
|
700.00
|
600.65
(0.23%)
|
16.27 |
Buy
|
|
|
Emami reported a flat consolidated revenue in 1QFY26 (vs. an est. of -3%), as growth in the core portfolio was offset by a sharp decline in the summercentric Talc and Heat powder.
|
|
16 Jun 2025
|
Emami
|
Khambatta Securities
|
602.05
|
842.00
|
573.70
(4.94%)
|
39.86 |
Buy
|
|
|
Emami reported healthy sales growth in 4Q FY25 despite tepid urban mass demand. In FY25, the company's domestic business launched over 25 new products.
|
|
04 Jun 2025
|
Emami
|
AUM Capital
|
602.05
|
708.00
|
593.90
(1.37%)
|
17.60 |
Buy
|
|
|
Emami Ltd (Emami) is one of the leading FMCG companies that manufactures and markets personal care and healthcare products. With over 550 diverse products, the company's portfolio includes brands such as Navratna, Boroplus, Fair & Handsome,...
|
|
22 May 2025
|
Emami
|
Sharekhan
|
602.05
|
745.00
|
604.00
(-0.32%)
|
23.74 |
Buy
|
|
|
Emami’s Q4FY25 performance was steady with consolidated revenues growing by 8.1% y-o-y to Rs. 963 crore, OPM declining 89 bps y-o-y to 22.8% and adjusted PAT rising by 9.2% y-o-y to Rs. 179 crore.
|
|
16 May 2025
|
Emami
|
Prabhudas Lilladhar
|
602.05
|
697.00
|
636.30
(-5.38%)
|
15.77 |
Accumulate
|
|
|
FY26 growth acceleration depends on repositioned Smart & Handsome, brightening cream response, Kesh King strategy and revival in Man company HMN delivered 6.5% revenue growth in FY25 led by healthy volume & pricing growth. Navratna, Dermicool, Boro Plus, and Healthcare drove robust performance while Male Grooming, Kesh King, and Strategic Subsidiaries dragged overall growth. The Man Company & Brillare will see some pick-up in FY26 led by increasing share on quick commerce platforms and 360-degree...
|
|
29 Jan 2025
|
Emami
|
Khambatta Securities
|
602.05
|
785.00
|
572.70
(5.12%)
|
30.39 |
Buy
|
|
|
Emami’s reported moderate sales growth in 3Q FY25, encountering economic and industry headwinds. Urban demand remained subdued due to rising food inflation and cash-strapped retail and wholesale trade.
|
|
28 Jan 2025
|
Emami
|
Sharekhan
|
602.05
|
670.00
|
555.55
(8.37%)
|
11.29 |
Buy
|
|
|
Emami’s Q3FY25 numbers were soft but performance was relatively better compared to peers, as the company posted mid-single digit volume growth and OPM beat expectations.
|
|
12 Nov 2024
|
Emami
|
Khambatta Securities
|
602.05
|
944.00
|
691.00
(-12.87%)
|
56.80 |
Buy
|
|
|
Emami’s reported fair sales growth in 2Q FY25 as higher food inflation negatively affected discretionary consumption. Management expects demand to improve in the second half of the financial year, driven by a predicted good winter season.
|
|
10 Nov 2024
|
Emami
|
Emkay
|
602.05
|
950.00
|
669.85
(-10.12%)
|
57.79 |
Buy
|
|
|
We remain positive on Emami, given the focus on execution to drive growth (with a professional team in place), the rebound in rural growth, increased thrust on urban (26% sales from Modern trade and Ecommerce), and hopes of a better season ahead.
|
|
10 Nov 2024
|
Emami
|
Anand Rathi
|
602.05
|
900.00
|
669.85
(-10.12%)
|
49.49 |
Buy
|
|
|
With Rs8.9bn revenue (vs. the Street’s Rs9.1bn estimate) and EBITDA atRs2.5bn (Rs2.5bn), Emami’s Q2 was broadly in line with estimates.
|
|
09 Nov 2024
|
Emami
|
Motilal Oswal
|
602.05
|
850.00
|
669.85
(-10.12%)
|
41.18 |
Buy
|
|
|
Emami reported 3% YoY sales growth in 2QFY25 (est. 5%). The domestic business grew 2.6% YoY, led by volume growth of 1.7% (est. 3%).
|
|
08 Nov 2024
|
Emami
|
Sharekhan
|
602.05
|
875.00
|
669.85
(-10.12%)
|
45.34 |
Buy
|
|
|
Emami’s Q2FY2025 operating performance missed the mark with domestic volume growth coming at 1.7% versus expectations of 3-4%. Consolidated OPM came in-line at 28.1%.
|
|
16 Sep 2024
|
Emami
|
Emkay
|
602.05
|
950.00
|
751.95
(-19.93%)
|
57.79 |
Buy
|
|
|
We hosted Emami’s management team—Mohan Goenka (Director), Manish Gupta (Head of Sales), and Rajesh Sharma (Sr VP finance and IR)—and a group of investors, as part of our Emkay Connect initiative.
|
|
29 Aug 2024
|
Emami
|
Khambatta Securities
|
602.05
|
943.00
|
813.00
(-25.95%)
|
|
Buy
|
|
|
Emami’s healthy sales growth during the quarter is attributable to robust domestic volume growth and a hot summer. Demand witnessed a sequential improvement in the 1Q FY25, particularly in rural markets, as the company also launched 8 new products.
|
|
01 Aug 2024
|
Emami
|
Motilal Oswal
|
602.05
|
950.00
|
824.10
(-26.94%)
|
|
Buy
|
|
|
Emami reported 10% YoY sales growth in 1QFY25 (est. 8%). The domestic business grew 10% YoY, led by 9% volume growth. There was a sequential improvement in demand in the rural market.
|
|
29 May 2024
|
Emami
|
Sharekhan
|
602.05
|
635.00
|
523.85
(14.93%)
|
Target met |
Buy
|
|
|
Emami’s Q4FY2024 operating performance was good as compared to the earlier quarter with a 6.4% volume growth; revenue grew by 7%; EBIDTA margin stood stable at 23.7%.
|
|
06 Nov 2023
|
Emami
|
Motilal Oswal
|
602.05
|
640.00
|
518.80
(16.05%)
|
Target met |
Buy
|
|
|
|
|
06 Nov 2023
|
Emami
|
Sharekhan
|
602.05
|
655.00
|
518.85
(16.04%)
|
Target met |
Buy
|
|
|
|